Query: Idiopathic pulmonary fibrosis cell signalling cascade fibroblast activation alveolar epithelial type II cell injury apoptosis regeneration mechanical stiffness TGF-β1 canonical and non-canonical pathways and crosstalk, potential targets for cell-based assay readouts

Idiopathic pulmonary fibrosis (IPF) is driven by a cascade of intertwined cellular and molecular events that begin with alveolar epithelial type II (ATII) cell injury and progress through fibroblast activation to end-stage tissue stiffening. Repetitive micro-injuries to ATII cells initiate apoptosis and impair their regenerative capacity, ultimately compromising alveolar repair. This loss of regenerative potential is further exacerbated by telomere dysfunction and cellular senescence, which push ATII cells into a dysfunctional state and may trigger recruitment of aberrant progenitor cells that contribute to pathological remodeling (brereton2021determinantsandeffects pages 42-45, xu2024definingtherole pages 51-54).

Central to IPF pathogenesis is the transforming growth factor-beta 1 (TGF-β1) signaling cascade. TGF-β1 exerts its effects via canonical pathways that depend on SMAD2/3 phosphorylation for transcriptional activation of profibrotic genes and non-canonical pathways that engage MAPK, PI3K/Akt, and other effector molecules. These signaling routes converge to promote fibroblast-to-myofibroblast differentiation, a process characterized by the upregulation of α-smooth muscle actin (α-SMA) and increased synthesis of extracellular matrix (ECM) proteins such as collagen, fibronectin, and hyaluronan (chakraborty2022emergingrolesof pages 14-16, samarelli2021molecularmechanismsand pages 9-10).

The crosstalk between TGF-β1 and other developmental and stress-induced pathways is a critical factor in establishing the fibrotic milieu. For instance, activated ATII cells, under the duress of repetitive injury, also show dysregulation of Wnt, Notch, Hippo, and hedgehog signaling pathways. This reactivation of developmental pathways not only impairs the normal repair and differentiation process but also propagates pro-fibrotic signals that further stimulate fibroblast activation (brereton2021determinantsandeffects pages 45-48, chakraborty2022emergingrolesof pages 16-17).

Mechanical stiffness is another pivotal component in the progression of IPF. The abnormal deposition and cross-linking of ECM components stiffen the lung tissue, and this increased rigidity is sensed by cells through integrins and mechanotransducers such as focal adhesion complexes and YAP/TAZ. This stiffness not only perpetuates TGF-β1 activation by facilitating the release of latent TGF-β1 from its binding proteins but also reinforces myofibroblast differentiation and ECM synthesis, forming a vicious self-sustaining loop of fibrosis (eley2018investigatingtherole pages 24-27, xu2024definingtherole pages 63-66).

In this context, several potential targets emerge for cell-based assay readouts. First, quantifying markers of ATII cell injury and apoptosis—for example, elevated caspase activity, increased p53 levels, or markers of ER stress—provides an assessment of epithelial dysfunction (chakraborty2022emergingrolesof pages 24-26, samarelli2021fibroticidiopathicinterstitial pages 5-6). Second, measuring TGF-β1 activation via canonical SMAD phosphorylation and non-canonical pathway effectors offers a direct readout of the fibrogenic stimulus (ma2022targetinggrowthfactor pages 2-4, samarelli2021molecularmechanismsand pages 9-10). Third, fibroblast activation can be tracked by the upregulation of α-SMA and the accumulation of ECM proteins such as collagen and fibronectin, which can be detected by immunostaining or biochemical assays (savin2022pulmonaryfibrosisas pages 7-9, xu2024definingtherole pages 63-66). Fourth, assays assessing cellular responses to mechanical stiffness, such as those employing substrates of varying rigidity to monitor mechanosensitive signaling (e.g., YAP/TAZ nuclear localization), can provide insights into how matrix stiffness modulates cell behavior and TGF-β1 activation (xu2024definingtherole pages 54-58, samarelli2021fibroticidiopathicinterstitial pages 6-8).

Overall, a robust panel of cell-based assays targeting ATII cell apoptosis/regeneration, TGF-β1 signaling (both canonical and non-canonical), fibroblast activation, and responses to mechanical stiffness would provide comprehensive insights into the multifaceted and interdependent signaling cascades driving IPF. This integrated approach not only elucidates disease mechanisms but also aids in the identification of therapeutic targets aimed at interrupting the fibrotic loop (brereton2021determinantsandeffects pages 42-45, xu2024definingtherole pages 63-66).

References:
1. (brereton2021determinantsandeffects pages 42-45): CJ Brereton. Determinants and effects of collagen cross-linking enzyme dysregulation in idiopathic pulmonary fibrosis. Unknown journal, 2021.

2. (brereton2021determinantsandeffects pages 45-48): CJ Brereton. Determinants and effects of collagen cross-linking enzyme dysregulation in idiopathic pulmonary fibrosis. Unknown journal, 2021.

3. (chakraborty2022emergingrolesof pages 14-16): Ashesh Chakraborty, Michal Mastalerz, Meshal Ansari, Herbert B. Schiller, and Claudia A. Staab-Weijnitz. Emerging roles of airway epithelial cells in idiopathic pulmonary fibrosis. Cells, 11:1050, Mar 2022. URL: https://doi.org/10.3390/cells11061050, doi:10.3390/cells11061050. This article has 55 citations and is from a peer-reviewed journal.

4. (chakraborty2022emergingrolesof pages 16-17): Ashesh Chakraborty, Michal Mastalerz, Meshal Ansari, Herbert B. Schiller, and Claudia A. Staab-Weijnitz. Emerging roles of airway epithelial cells in idiopathic pulmonary fibrosis. Cells, 11:1050, Mar 2022. URL: https://doi.org/10.3390/cells11061050, doi:10.3390/cells11061050. This article has 55 citations and is from a peer-reviewed journal.

5. (chakraborty2022emergingrolesof pages 24-26): Ashesh Chakraborty, Michal Mastalerz, Meshal Ansari, Herbert B. Schiller, and Claudia A. Staab-Weijnitz. Emerging roles of airway epithelial cells in idiopathic pulmonary fibrosis. Cells, 11:1050, Mar 2022. URL: https://doi.org/10.3390/cells11061050, doi:10.3390/cells11061050. This article has 55 citations and is from a peer-reviewed journal.

6. (eley2018investigatingtherole pages 24-27): J Eley. Investigating the role of mtor signalling in mediating the pro-fibrotic effects of tgf-β1. Unknown journal, 2018.

7. (ma2022targetinggrowthfactor pages 2-4): Hongbo Ma, Shengming Liu, Shanrui Li, and Yong Xia. Targeting growth factor and cytokine pathways to treat idiopathic pulmonary fibrosis. Frontiers in Pharmacology, Jun 2022. URL: https://doi.org/10.3389/fphar.2022.918771, doi:10.3389/fphar.2022.918771. This article has 35 citations and is from a peer-reviewed journal.

8. (samarelli2021fibroticidiopathicinterstitial pages 5-6): Anna Valeria Samarelli, Roberto Tonelli, Alessandro Marchioni, Giulia Bruzzi, Filippo Gozzi, Dario Andrisani, Ivana Castaniere, Linda Manicardi, Antonio Moretti, Luca Tabbì, Stefania Cerri, Bianca Beghè, Massimo Dominici, and Enrico Clini. Fibrotic idiopathic interstitial lung disease: the molecular and cellular key players. International Journal of Molecular Sciences, 22:8952, Aug 2021. URL: https://doi.org/10.3390/ijms22168952, doi:10.3390/ijms22168952. This article has 51 citations and is from a peer-reviewed journal.

9. (samarelli2021fibroticidiopathicinterstitial pages 6-8): Anna Valeria Samarelli, Roberto Tonelli, Alessandro Marchioni, Giulia Bruzzi, Filippo Gozzi, Dario Andrisani, Ivana Castaniere, Linda Manicardi, Antonio Moretti, Luca Tabbì, Stefania Cerri, Bianca Beghè, Massimo Dominici, and Enrico Clini. Fibrotic idiopathic interstitial lung disease: the molecular and cellular key players. International Journal of Molecular Sciences, 22:8952, Aug 2021. URL: https://doi.org/10.3390/ijms22168952, doi:10.3390/ijms22168952. This article has 51 citations and is from a peer-reviewed journal.

10. (samarelli2021molecularmechanismsand pages 9-10): Anna Valeria Samarelli, Valentina Masciale, Beatrice Aramini, Georgina Pamela Coló, Roberto Tonelli, Alessandro Marchioni, Giulia Bruzzi, Filippo Gozzi, Dario Andrisani, Ivana Castaniere, Linda Manicardi, Antonio Moretti, Luca Tabbì, Giorgia Guaitoli, Stefania Cerri, Massimo Dominici, and Enrico Clini. Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development. International Journal of Molecular Sciences, 22:12179, Nov 2021. URL: https://doi.org/10.3390/ijms222212179, doi:10.3390/ijms222212179. This article has 76 citations and is from a peer-reviewed journal.

11. (savin2022pulmonaryfibrosisas pages 7-9): Innokenty A. Savin, Marina A. Zenkova, and Aleksandra V. Sen’kova. Pulmonary fibrosis as a result of acute lung inflammation: molecular mechanisms, relevant in vivo models, prognostic and therapeutic approaches. International Journal of Molecular Sciences, 23:14959, Nov 2022. URL: https://doi.org/10.3390/ijms232314959, doi:10.3390/ijms232314959. This article has 145 citations and is from a peer-reviewed journal.

12. (xu2024definingtherole pages 51-54): Z Xu. Defining the role of epithelial lkb1 in idiopathic pulmonary fibrosis. Unknown journal, 2024.

13. (xu2024definingtherole pages 54-58): Z Xu. Defining the role of epithelial lkb1 in idiopathic pulmonary fibrosis. Unknown journal, 2024.

14. (xu2024definingtherole pages 63-66): Z Xu. Defining the role of epithelial lkb1 in idiopathic pulmonary fibrosis. Unknown journal, 2024.
